Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 9,533 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 29, 2026, 10:24 PM EDT
Available No phase listed Expanded access

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134
View directory record Official record
Conditions
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Brexucabtagene Autoleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Not listed No phase listed Observational

The Global cVAD Study

NCT04136392
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
ABIOMED, Inc. hemodynamic support devices
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 29, 2026, 10:24 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471
View directory record Official record
Conditions
Crohn's Disease
Interventions
Guselkumab, Golimumab, JNJ-78934804, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
90
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

NCT00007007
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Radiation Toxicity
Interventions
management of therapy complications, quality-of-life assessment
Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
223
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 174 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 29, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

NCT01771471
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
NuQu, Placebo
Biological · Other
Lead sponsor
ISTO Technologies, Inc.
Industry
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 29, 2026, 10:24 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Oxalate Formation From Ascorbic Acid

NCT04603898
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet, Carbon-13 Ascorbic Acid Oral Load
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Nutrition Intervention in Treating Women With Breast Cancer

NCT00002564
View directory record Official record
Conditions
Breast Cancer
Interventions
educational intervention, therapeutic dietary intervention
Other · Procedure
Lead sponsor
Institute for Cancer Prevention (IFCP)
Other
Eligibility
48 Years to 78 Years · Female only
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
infliximab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 29, 2026, 10:24 PM EDT
Not listed Phase 3 Interventional

Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D

NCT01534234
View directory record Official record
Conditions
Heart Failure NYHA Class III and Ambulatory IV
Interventions
PARADYM RF SONR
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2019 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2 Interventional Results available

Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma

NCT00941798
View directory record Official record
Conditions
Asthma
Interventions
QMF149 Twisthaler®, Mometasone Twisthaler®
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 70 Years
Enrollment
2,283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
92
States / cities
Birmingham, Alabama • Buena Park, California • Encinitas, California + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 29, 2026, 10:24 PM EDT
Completed No phase listed Observational Results available

An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI

NCT04717492
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Observational
Other
Lead sponsor
University of Minnesota
Other
Eligibility
35 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

NCT05133336
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients

NCT01061736
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo (for sarilumab), Methotrexate, Folic Acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
45
States / cities
Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 29, 2026, 10:24 PM EDT
Terminated Phase 3 Interventional

Surgery for Vocal Cord Paralysis

NCT00064571
View directory record Official record
Conditions
Unilateral Vocal Cord Paralysis
Interventions
vocal fold medialization, vocal fold reinnervation
Procedure
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
12
States / cities
Birmingham, Alabama • Irvine, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2006 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV

NCT03692611
View directory record Official record
Conditions
Chronic Pain
Interventions
Skills TO Manage Pain (STOMP), Comparison group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 89 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma

NCT04402632
View directory record Official record
Conditions
Subdural Hematoma
Interventions
Surgical Management, Onyx™ Liquid Embolic System (LES) Embolization, Observation Only
Procedure · Device · Other
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 29, 2026, 10:24 PM EDT
Not yet recruiting Phase 3 Interventional

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

NCT07291102
View directory record Official record
Conditions
Medulloblastoma
Interventions
Bridging Chemotherapy, Induction Cycles A1-A3, Induction Cycles A4-5, Consolidation Cycle A6, HIT-SKK Chemotherapy Cycles B1-3, Modified HIT-SKK Cycle B4-5
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 5 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2038
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Completed No phase listed Observational

Associating Renal Transplantation With the ITN Signature of Tolerance

NCT01516177
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Recruiting Phase 2 Interventional

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Interventions
ACP-211, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Chino, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 10:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 29, 2026, 10:24 PM EDT